| |
|
Papillary serous
carcinoma |
Peritoneal epithelioid
mesothelioma |
Notes |
|
Calretinin |
1/161,
4/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. <1% of cells; 1
case, 1-25% of cells; 3 cases)2,
0/23(Positivity
required nuclear staining: 2 cases showed focal cytoplasmic staining)3, 5/134,
8/265, 14/45(51-75% of cells: 3
cases [2 of these 3 cases were also strongly positive for BerEP4
but were negative for CK5/6; one was negative for MOC-31, the
other showed trace positivity; electron microscopy was required
to establish the diagnosis of serous carcinoma], 26-50% of cells:
3 cases, 1-25% of cells: 7 cases, <1% of cells: 1 case.)6, 5/40(51%
to 75% of cells: 2 cases, 26% to 50% of cells; 3 cases)17, 0/3619 |
3/31,
35/35(1-25%
of cells; 3 cases, 26-50% of cells; 4 cases, 51-75% of cells;
11 cases, >75% of cells; 17 cases.)2,
28/32(staining
was both nuclear and cytoplasmic)3,
40/40(>75%
of cells: 30 cases, 51-75% of cells: 9 cases, 26-50% of cells:
1 case. Staining was both cytoplasmic and nuclear.)6, 15/15(nuclear
and cytoplasmic: >75% of cells: 12 cases, 51% to 75% of cells:
3 cases)17
|
Useful but the
positivity of some serous carcinomas makes this marker less than
specific. |
CK5/6 |
11/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. <1% of cells; 5
cases ,1-25% of cells; 5 cases,26-50% of cells; 1 case)2, 5/233,
11/327, 9/265, 14/45(26-50%
of cells: 4 cases, 1-25% of cells: 7 cases, <1% of cells: 3
cases.)6, 11/40(26%
to 50% of cells: 5 cases, 1% to 25% of cells: 6 cases)17 |
35/35(26-50%
of cells; 6 cases, 51-75% of cells; 8 cases, >75% of cells;
21 cases)2,
17/323, 37/40(>75% of 10 cells:
cases, 51-75% of cells: 12 cases, 26-50% of cells: 11 cases, 1-25%
of cells: 3 cases, <1% of cells: 1 case. Staining was cytoplasmic.)6, 14/15(>75%
of cells: 8 cases, 51% to 75% of cells: 4 cases, 26% to 50% of
cells: 2 cases)17 |
This marker is
of limited value in this context. |
Thrombomodulin |
7/20(staining
was focal, light and membranous)8,
1/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. <1% of cells in
1 case)2, 6/23(staining
was focal)3,
2/45(1-25%
of cells: 1 case, <1% of cells: 1 case.)6,
2/40(1%
to 25% of cells : 2 cases)17 |
6/18(staining
was focal and membranous)8,
26/35(1-25%
of cells; 6 cases, 26-50% of cells; 9 cases, 51-75% of cells;
9 cases, >75% of cells; 2 cases.)2,
18/32(staining
was focal and membranous)3,
29/40(>75%
of cells: 4 cases, 51-75% of cells: 7 cases, 26-50% of cells:
11 cases, 1-25% of cells: 6 cases, <1% of cells: 1 case. Staining
was membranous)6,
9/15(>75%
of cells: 1 case, 51% to 75% of cells: 1 case, 26% to 50% of cells:
1 case, 1% to 25% of cells: 6 cases)17 |
Results vary
between studies. |
D2-40 |
6/45(26-50%
of cells: 2 cases, 1-25% of cells: 4 cases. Staining was of the
apical cell membrane)6,
98/169(This
was a study of cell blocks from serous effusions. 138 of these
were serous carcinomas of ovary, primary of peritoneum (23 cases)
or of Fallopian tube (8 cases). The paper does not state how many
of the serous cases were positive. In 13 cases, 11-100% of the
cells were positive, in 85 cases 10% or less of the cells were
positive.)16,
8/40(26%
to 50% of cells; 3 cases, 1% to 25% of cells: 5 cases)17 |
37/40(>75%
of cells: 17 cases, 51-75% of cells: 9 cases, 26-50% of cells:
7 cases, 1-25% of cells: 4 cases. Well differentiated tumours
show staining of the apical cell membrane. Less well differentiated
tumours show circumferential or discontinuous membrane staining.)6, 14/15(>75%
of cells: 6 cases, 51% to 75% of cells: 3 cases, 26% to 50% of
cells; 3 cases, 1% to 25% of cells: 2 cases)17 |
The evidence
from these two studies is conflicting. |
Podoplanin |
6/45(26-50%
of cells: 4 cases, 1-25% of cells: 2 cases. Staining was of the
apical cell membrane.) 6 |
37/40(>75%
of cells: 16 cases, 51-75% of cells: 8 cases, 26-50% of cells:
9 cases, 1-25% of cells: 4 cases. These were the same 37 cases
that stained with D2-40 and the staining pattern was similar.)
6 |
The specificity
for mesothelioma is higher than that of calretinin but the sensitivity
is lower. |
BerEP4 |
25/309,
45/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. 1-25% of cells; 4 cases,
26-50% of cells; 5 cases, 51-75% of cells; 14 cases, >75% of
cells; 22 case)2,
3/610, 20/233, 45/45(>75%
of cells: 34 cases, 51-75% of cells: 8 cases, 26-50% of cells:
2 cases, 1-25% of cells: 1 case. Staining was membranous)6, 38/40(>75%
of cells: 36 cases, 51-75% of cells: 2 cases)17 |
4/35(<1%
of cells; 1 case, 26-50% of cells; 3 cases.)2,
3/323, 5/40(1-25% of cells: 3
cases, <1% of cells: 2 cases. Staining was membranous)6, 1/15(1%
to 25% of cells: 1 case)17 |
Strong staining
is a useful marker for serous carcinomas |
B72.3 |
47/4711,
33/4612, 37/4413, 13/2014,
10/1015, 27/309, 39/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. <1% of cells; 3
cases ,1-25% of cells; 12 cases, 26-50% of cells; 13 cases, 51-75%
of cells; 8 cases, >75% of cells; 3 cases)2,
33/45(>75%
of cells: 3 cases, 51-75% of cells: 4 cases, 26-50% of cells:
6 cases, 1-25% of cells: 13 cases, <1% of cells: 7 cases. Staining
was apical membranous.)6,
29/40(>75%
of cells: 1 case, 51% to 75% of cells: 2 cases, 26% to 50% of
cells: 3 cases, 1% to 25% of cells: 23 cases)17 |
0/2812,
3/10(in
3 cases, less than 1% of cells were positive)14,
0/2015, 0/352, 0/406,
0/1517 |
This marker has
specificity for serous carcinomas but limited sensitivity. |
CD15 |
34/4612,
32/4413, 6/2014, 8/1015,
17/309, 28/45(30 ovarian [10 primary
and 20 metastatic to peritoneum] and 15 primary papillary serous
carcinomas of peritoneum. <1% of cells; 2 cases, 1-25% of cells;
9 cases, 26-50% of cells; 10 case, 51-75% of cells; 5 cases, >75%
of cells; 2 cases)2,
7/233, 26/45(51-75% of cells: 7
cases, 26-50% of cells: 10 cases, 1-25% of cells: 9 cases. Staining
was membranous)6,
18/40(1%
to 25% of cells: 18 cases)17 |
3/2812,
0/414, 3/2015,
0/352, 2/323,
0/406, 0/1517 |
This marker has
specificity for serous carcinomas but low sensitivity. |
MOC-31 |
44/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. 1-25% of cells; 4 cases,
26-50% of cells; 16 cases, 51-75% of cells; 19 cases, >75%
of cells; 5 cases)2,
44/45(>75%
of cells: 29 cases, 51-75% of cells: 9 cases, 26-50% of cells:
4 cases, 1-25% of cells: 1 case, <1% of cells: 1 case. Staining
was both cytoplasmic and membrane.)6 |
1/35(1-25%
of cells; 1 case.)2,
2/40(1-25%
of cells: 1 case, <1% of cells: 1 case.)6 |
This marker may
be very helpful in this context, with a higher specificity than
Ber-EP4.
|
BG-8 |
33/45(>75%
of cells: 8 cases, 51-75% of cells: 6 cases, 26-50% of cells:
9 cases, 1-25% of cells: 8 cases, <1% of cells: 2 cases.)6 |
1/40(<1%
of cells: 1 case.)6 |
|
CD44H |
5/23(staining
was membranous and seen in up to 50% of tumour cells)3 |
15/32(staining
was thick and membranous)3 |
No value |
Ca19-9 |
31/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% 0f cells; 3
case, 1-25% of cells; 16 cases, 26-50% of cells; 9 cases, 51-75%
of cells; 2 cases, >75% of cells; 1 case)2,
30/45(51-75%
of cells: 1 case, 26-50% of cells: 13 cases, 1-25% of cells: 15
cases, <1% of cells: 1 case.)6,
24/40(1%
to 35% of cells: 24 cases)17 |
0/352,
0/406, 0/1517 |
This marker has
specificity for serous carcinomas but low sensitivity. |
Ca-125 |
42/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% of cells; case,
1-25% of cells; 17 cases, 26-50% of cells; 11 cases, 51-75% of
cells; 13 cases, >75% of cells; 1 case)2,
21/23(staining
was membranous)3 |
33/35(1
case, 1-25% of cells; 12 cases, 26-50% of cells; 9 cases, 51-75%
of cells; 8 cases, >75% of cells; 3 cases.), 8/32(staining was membranous)3 |
Limited value |
pCEA |
7/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. <1% of cells; 3
cases ,1-25% of cells; 3 cases,51-75% of cells; 1 case)2, 2/233 |
3/323 |
No value, due
to the low rate of positivity in serous carcinomas |
mCEA |
1/233 |
0/323 |
No value, due
to the low rate of positivity in serous carcinomas |
HBME-1 |
40/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. 1-25% of cells; 4 cases,
26-50% of cells; 6 cases, 51-75% of cells; 11 cases, >75% of
cells; 19 case)2 |
31/35(1-25%
of cells; 3 cases, 26-50% of cells; 5 cases, 51-75% of cells;
7 cases, >75% of cells; 16 cases.)2 |
No value |
PLAP |
11/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% 0f cells; 1
case, 1-25% of cells; 7 cases, 26-50% of cells; 3 cases)2 |
0/352 |
No value |
44-3A6 |
28/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% of cells; 3
cases, 1-25% of cells; 10 cases, 26-50% of cells; 9 cases, 51-75%
of cells; 6 cases.)2 |
16/35(<1%
of cell; 1 case, 1-25% of cells; 7 cases, 26-50% of cells; 6 cases,
51-75% of cells; 2 cases.)2 |
No value |
S-100 |
14/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% of cells; 3
case, 1-25% of cells; 7 cases, 26-50% of cells; 4 cases.)2 |
0/352 |
No value |
Vimentin |
15/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. < 1% of cells; 4
cases, 1-25% of cells; 11 cases.)2 |
9/35(<1%
of cells; 1 case, 1-25% of cells; 8 cases.)2 |
No value |
EMA |
45/45(30
ovarian [10 primary and 20 metastatic to peritoneum] and 15 primary
papillary serous carcinomas of peritoneum. 1-25% of cells; 3 cases,
26-50% of cells; 9 cases, 51-75% of cells; 15 cases, >75% of
cells; 18 cases.)2 |
35/35(1-25%
of cells; 3 cases, 26-50% of cells; 2 cases, 51-75% of cells;
7 cases, >75% of cells; 23 cases.)2 |
|
h-Caldesmon |
2/40(positivity
of 1% to 25% of cells in 1 case, 26 to 50% of cells in 1 case)17, 0/255(0/92
serous borderline tumours of the ovary, 0/10 low grade serous
carcinomas of the ovary, 0/152 high grade serous carcinomas of
the ovary)18 |
15/15(Positivity
of >75% of cells in 11 cases, 51% to 75% of cells in 4 cases.
The primary antibody was applied at a dilution of
1:100) 17,
1/50(1/24
pleural malignant mesotheliomas, 0/23 peritoneal malignant mesotheliomas,
0/2 well differentiated papillary mesotheliomas, 0/1 multiloculated
cystic mesothelioma. the primary antibody was used at a
dilution of 1:300. staining was repeated in 17 cases at
a dilution of 1:100 and remained negative)18 |
Conflicting results |
ER |
38/40(>75%
of cells: 25 cases, 51% to 75% of cells: 6 cases, 25% to 50% of
cells: 7 cases)17 |
0/1517,
2/17(the
two cases positive for pax-2 where also positive for oestrogen
receptors but not for progesterone receptors)1 |
Useful, based
on one study |
PR |
26/40(>75%
of cells: 1 case, 51% to 75% of cells: 3 cases, 25% to 50% of
cells: 10 cases, 1% to 25% of cells: 12 cases)17 |
0/1517 |
|
| PAX2 |
24/3619 |
2/17(mesotheliomas
in female patients: the two cases positive for pax-2 where also
positive for oestrogen receptors but not for progesterone receptors)19 |
Useful, based on
one study |
| PAX8 |
253/254(92/92
serous borderline tumours of the ovary, 10/10 low grade serous
carcinomas of the ovary, 151/152 high grade serous carcinomas
of the ovary)18 |
5/50(0/24
pleural malignant mesotheliomas, 2/23 peritoneal malignant mesotheliomas,
2/2 well differentiated papillary mesotheliomas, 1/1 multiloculated
cystic mesothelioma)18 |
Useful, based on
one study |
| Tenascin-X |
|
|
|
| |
|
|
|
This page last revised 29.4.2010.